StockMirror — Stock Screener

JSLL Q4 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Jeena Sikho Lifecare reported a stellar full-year FY26 with 71% revenue growth, 149% EBITDA growth, and 177% PAT growth. The business model, combining preventive healthcare services (Panchakarma) with high-margin product sales, is demonstrating strong unit economics and operating leverage. Q4 FY26 saw a sequential dip in reported profit solely due to exceptional one-time charges of ~INR 21 crores, as confirmed by management and their new auditors, Grant Thornton. Underlying business momentum remains strong, with management guiding for a minimum PAT of INR 300 crores in FY27. The company is positioned to benefit from government tailwinds (Ayushman Bharat) and growing insurance penetration. Key risks include sensitivity to macro events and successful execution of its ambitious bed expansion and new product launch plans.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

The company has demonstrated that it can achieve high revenue growth (71%) while simultaneously expanding margins (1360 bps YoY). Management's strategy focuses on a capital-light model with proven unit economics that supports both expansion and profitability. ,

About Jeena Sikho Lifecare Limited

Jeena Sikho Lifecare Limited (JSLL) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More